As of 2025-05-20, the Intrinsic Value of Guangzhou Boji Medical & Biotechnological Co Ltd (300404.SZ) is 13.32 CNY. This 300404.SZ valuation is based on the model Discounted Cash Flows (Growth Exit 10Y). With the current market price of 8.22 CNY, the upside of Guangzhou Boji Medical & Biotechnological Co Ltd is 62.00%.
The range of the Intrinsic Value is 7.92 - 34.99 CNY
Based on its market price of 8.22 CNY and our intrinsic valuation, Guangzhou Boji Medical & Biotechnological Co Ltd (300404.SZ) is undervalued by 62.00%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (3.87) - (1.00) | (1.58) | -119.2% |
| DCF (Growth 10y) | 7.92 - 34.99 | 13.32 | 62.0% |
| DCF (EBITDA 5y) | 12.45 - 16.44 | 14.38 | 75.0% |
| DCF (EBITDA 10y) | 24.79 - 36.51 | 30.21 | 267.6% |
| Fair Value | 1.05 - 1.05 | 1.05 | -87.17% |
| P/E | 0.78 - 2.05 | 1.32 | -83.9% |
| EV/EBITDA | 0.78 - 4.61 | 2.23 | -72.9% |
| EPV | (0.12) - (0.40) | (0.26) | -103.2% |
| DDM - Stable | 0.47 - 2.39 | 1.43 | -82.6% |
| DDM - Multi | 8.03 - 31.23 | 12.70 | 54.5% |
| Market Cap (mil) | 3,148.75 |
| Beta | 1.43 |
| Outstanding shares (mil) | 383.06 |
| Enterprise Value (mil) | 2,924.75 |
| Market risk premium | 6.13% |
| Cost of Equity | 7.95% |
| Cost of Debt | 5.00% |
| WACC | 7.89% |